- CA$7.76m
- CA$4.22m
- CA$5.07m
- 55
- 60
- 35
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.28 | ||
| Price to Tang. Book | 0.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.65 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.3% | ||
| Return on Equity | -26.49% | ||
| Operating Margin | -168.09% | ||
Financial Summary
| Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 5.61 | 5.44 | 4.12 | 3.9 | 5.07 | n/a | n/a | -9.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RAMM Pharma Corp. is a Canada-based company that is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a diversified international production and sales platform. The Company operates a pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or use in several Latin American countries. The Company has a pipeline of products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at its formulation facility in Montevideo, Uruguay. The Company's brands include NettaPet and NettaVet. Its subsidiaries include Canapar Corp., HemPoland S.p. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
Directors
- Last Annual
- October 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- July 21st, 1987
- Public Since
- November 8th, 2019
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange- Shares in Issue
- 119,389,317
- Address
- 82 Richmond St. E, TORONTO, M5C 1P1
- Web
- https://www.wearerammpharma.com/
- Phone
- +1 4168487744
- Auditors
- Zeifman LLP
Upcoming Events for RAMM
Similar to RAMM
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
What is the Ramm Pharma share price?
As of Today at 19:18 UTC, shares in Ramm Pharma are trading at CA$0.07. This share price information is delayed by 15 minutes.
How has the Ramm Pharma share price performed this year?
Shares in Ramm Pharma last closed at CA$0.07 and the price had moved by -7.14% over the past 365 days. In terms of relative price strength the Ramm Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -11.89% over the past year.
What are the analyst and broker recommendations for Ramm Pharma?
There is no consensus recommendation for this security.
What is the Ramm Pharma dividend yield?
Ramm Pharma does not currently pay a dividend.
Does Ramm Pharma pay a dividend?
Ramm Pharma does not currently pay a dividend.
When does Ramm Pharma next pay dividends?
Ramm Pharma does not currently pay a dividend.
How do I buy Ramm Pharma shares?
To buy shares in Ramm Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ramm Pharma?
As of the previous close price of CA$0.07, shares in Ramm Pharma had a market capitalisation of CA$7.76m.
Where are Ramm Pharma shares listed?
Here are the trading details for Ramm Pharma:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: RAMM
What kind of share is Ramm Pharma?
Based on an overall assessment of its quality, value and momentum Ramm Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ramm Pharma share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Ramm Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ramm Pharma. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +13.54%.
As of the last closing price of CA$0.07, shares in Ramm Pharma were trading -41.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ramm Pharma PE Ratio?
The Ramm Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ramm Pharma?
We do not have data on Ramm Pharma's directors